Tag: Nasdaq:ARTL

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced its presentation of new data at the British Pain Conference held in Newport, Wales, UK on June 3-5, 2025 (https://bpsasm.org/) that further validates the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating osteoarthritis (OA) pain.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsNasdaq:ARTL

InventHelp Inventor Develops New Beverage Accessory (TLS-807)

BexBack Launches Limited-Time $50 Bonus, 100% Deposit Bonus Match, 100x Leverage, and No KYC Amid Bitcoin Surge Past $100K

Lifeway Foods Comments on Edward and Ludmila Smolyansky’s Consent Solicitation and Urges Shareholders to Disregard the Unlawful Consent Solicitation Statement

Tag: Nasdaq:ARTL

Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us